Jinhwan Cho

Mr. Jinhwan Cho


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2021 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
ZHZohaib Hussain
Zohaib Hussain
SKSeoungkyun Kim
Seoungkyun Kim
JCJinhwan Cho
Jinhwan Cho
GSGyudae Sim
Gyudae Sim
YPYoungjune Park
Youngjune Park
IKInchan Kwon
Inchan Kwon

1 December 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
MGMoon Soo Gil
Moon Soo Gil
JCJinhwan Cho
Jinhwan Cho
TTThavasyappan Thambi
Thavasyappan Thambi
VPV.H. Giang Phan
V.H. Giang Phan
IKInchan Kwon
Inchan Kwon
DLDoo Sung Lee
Doo Sung Lee

21 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JCJinhwan Cho
Jinhwan Cho
SLSung In Lim
Sung In Lim
BYByung Seop Yang
Byung Seop Yang
YHYoung S. Hahn
Young S. Hahn
IKInchan Kwon
Inchan Kwon
Extension of the serum half-life is an important issue in developing new therapeutic proteins and expanding applications of existing therapeutic proteins. Conjugation of fatty acid, a natural human serum albumin ligand, to a therapeutic protein/peptide was developed as a technique to extend the serum half-life in vivo by taking advantages of unusually long serum half-life of human serum albumin (HSA). However, for broad applications of fatty acid-conjugation, several issues should be addressed, including a poor solubility of fatty acid and a substantial loss in the therapeutic activity. Therefore, herein we systematically investigate the conditions and components in conjugation of fatty acid to a therapeutic protein resulting in the HSA binding capacity without compromising therapeutic activities. By examining the crystal structure and performing dye conjugation assay, two sites (W160 and D112) of urate oxidase (Uox), a model therapeutic protein, were selected as sites for fatty acid-conjugation. Combination of site-specific incorporation of a clickable p-azido-L-phenylalanine to Uox and strain-promoted azide-alkyne cycloaddition allowed the conjugation of fatty acid (palmitic acid analog) to Uox with the HSA binding capacity and retained enzyme activity. Deoxycholic acid, a strong detergent, greatly enhanced the conjugation yield likely due to the enhanced solubility of palmitic acid analog.

1 August 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
JCJinhwan Cho
Jinhwan Cho
SKSeong Han Kim
Seong Han Kim
BYByungseop Yang
Byungseop Yang
JJJae Min Jung
Jae Min Jung
IKInchan Kwon
Inchan Kwon
DLDoo Sung Lee
Doo Sung Lee

16 April 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MBMijeong Bak
Mijeong Bak
JPJunyong Park
Junyong Park
KMKiyoon Min
Kiyoon Min
JCJinhwan Cho
Jinhwan Cho
JSJihyoun Seong
Jihyoun Seong
IKInchan Kwon
Inchan Kwon
The number of therapeutic peptides for human treatment is growing rapidly. However, their development faces two major issues: the poor yield of large peptides from conventional solid-phase synthesis, and the intrinsically short serum half-life of peptides. To address these issues, we investigated a platform for the production of a recombinant therapeutic peptide with an extended serum half-life involving the site-specific conjugation of human serum albumin (HSA). HSA has an exceptionally long serum half-life and can be used to extend the serum half-lives of therapeutic proteins and peptides. We used glucagon-like-peptide 1 (GLP-1) as a model peptide in the present study. A “clickable” non-natural amino acid—p-azido-l-phenylalanine (AzF)—was incorporated into three specific sites (V16, Y19, and F28) of a GLP-1 variant, followed by conjugation with HSA through strain-promoted azide–alkyne cycloaddition. All three HSA-conjugated GLP-1 variants (GLP1_16HSA, GLP1_19HSA, and GLP1_28HSA) exhibited comparable serum half-lives in vivo. However, the three GLP1_HSA variants had different in vitro biological activities and in vivo glucose-lowering effects, demonstrating the importance of site-specific HSA conjugation. The platform described herein could be used to develop other therapeutic peptides with extended serum half-lives.

1 May 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
JCJinhwan Cho
Jinhwan Cho
JPJunyong Park
Junyong Park
SKSongwon Kim
Songwon Kim
JKJong Chul Kim
Jong Chul Kim
GTGiyoong Tae
Giyoong Tae
IKInchan Kwon
Inchan Kwon